Tuesday, February 27, 2018

Senti Biosciences Snags $53M For Gene Therapy

South San Francisco-based Senti Biosciences, a company developing gene- and cell-based therapies for challenging diseases, has raised $53M in a funding round, the company said on Tuesday. The funding was led by New Enterprise Associates, and also included 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital. Dr. Tim Lu is co-founder and CEO of Senti Biosciences. More information »